Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 vaccines are being developed and implemented with unprecedented speed. Accordingly, trials considered ethical at their inception may quickly become concerning. We provide recommendations for Data and Safety Monitoring Boards (DSMBs) on monitoring the ethical acceptability of COVID-19 vaccine trials, focusing on placebo-controlled trials in low- and middle-income countries.

Original publication

DOI

10.1093/cid/ciab239

Type

Journal article

Journal

Clin Infect Dis

Publication Date

24/03/2021

Keywords

COVID-19 Vaccines, Clinical Trials Data Monitoring Committees, Ethics, Research, SARS-CoV-2, Standard of Care